Millie
your market intelligence analyst
Search Results
88 results
Your search is now limited to «Takeda» expert search.
ENDPOINTS 10/11/2019 10:48
The recruitment of Mendelman — an alumni of Takeda Vaccines, MedImmune and Merck — spells good news for the microcap biotech, whose stock suffered a rout after last month’s setback.
More from ENDPOINTS:
FiercePharmaManufacturing 10/11/2019 05:33
Takeda pens Prometheus pact to find novel IBD targets Gastroenterology is one of Takeda’s key focus areas, led by its fast-growing inflammatory bowel disease (IBD) therapy Entyvio.
More from FiercePharmaManufacturing:
Korean Biomedical Review 10/11/2019 01:36
Kim Young-buk, the leader of Korea Democratic Pharmaceutical Union at Takeda Pharmaceutical Korea, said that the union plans to hold rallies and picketing in front of the company’s Japanese headquarters.
More from Korean Biomedical Review:
FierceMedicalDevices 10/04/2019 07:55
Takeda will handle all drug development and commercialization from discovery onward, resulting in an arrangement designed to tap into the companies respective strengths.
More from FierceMedicalDevices:
PR Newswire 10/03/2019 18:14
The collaboration combines the proprietary bioinformatics discovery platform and companion diagnostic tools developed by Prometheus Biosciences with Takeda's expertise in gastroenterology and drug development, in order to discover and advance up to three targeted IBD therapeutics and companion diagnostics.
More from PR Newswire:
PharmTech.com 09/27/2019 23:39
GE Healthcare announced on Nov. 11, 2014 an alliance agreement with Takeda Pharmaceutical to research and develop therapeutic drugs to target liver diseases.
More from PharmTech.com:
Business Wire 09/27/2019 09:00
The collaboration is focused on using [F-18]MK-6240 as a biomarker in Takeda’s neurodegenerative disease research.
More from Business Wire:
Benzinga 09/26/2019 07:54
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks. (Biotech stocks that hit 52-week highs Sept. 25.). Coherus Biosciences Inc (NASDAQ: ). The Medicines Company (NASDAQ: ). Down In The Dumps. (Biotech stocks that hit 52-week lows Sept. 25.). Adaptive Biotechnologies Corp (NASDAQ: ). Advaxis, Inc. (NASDAQ: ). AnaptysBio Inc (NASDAQ: ). Aridis Pharmaceuticals Inc (NASDAQ: ). AzurRx BioPharma Inc (NASDAQ: ) ( lackadaisical efficacy data for pancreatic insufficiency drug). BridgeBio Pharma Inc (NASDAQ: ). Calithera Biosciences Inc (NASDAQ: ). China SXT Pharmaceuticals Inc (NASDAQ: ). Catalyst Biosciences Inc (NASDAQ: ). Cellectis SA (NASDAQ: ). CytomX Therapeutics Inc (NASDAQ: ). DelMar Pharmaceuticals
More from Benzinga:
pharmaphorum 09/26/2019 07:20
Takeda completed its takeover of Shire in January, shortly after ratings agency Moody’s cut the Japanese company’s credit rating from A2 to BAA2, two points above junk status.
More from pharmaphorum:
Takeda Pharmaceutical 09/24/2019 22:33
Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience.
More from Takeda Pharmaceutical:
Bionity.com 09/24/2019 07:00
The collaboration combines Evotec’s ability to effectively drive fully integrated drug discovery programmes with Takeda’s strategic insights into transformative therapeutic approaches in Takeda’s four core therapeutic areas: Oncology, Gastroenterology, Neuroscience and Rare Diseases, as well as Takeda’s development and commercialisation expertise.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications